Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Effects of rilpivirine, 17β-estradiol and β-naphthoflavone on the inflammatory status of release of adipocytokines in 3T3-L1 adipocytes in vitro.

Tytuł:
Effects of rilpivirine, 17β-estradiol and β-naphthoflavone on the inflammatory status of release of adipocytokines in 3T3-L1 adipocytes in vitro.
Autorzy:
Behl S; School of Forensic and Applied Sciences, University of Central Lancashire, Preston, Lancashire, PR1 2HE, England, UK. .
Adem A; Department of Pharmacology, United Arab Emirates University, Al Ain, United Arab Emirates.
Hussain A; School of Life Sciences, Manipal University, Academic City, Dubai, United Arab Emirates.
Singh J; School of Forensic and Applied Sciences, University of Central Lancashire, Preston, Lancashire, PR1 2HE, England, UK.
Źródło:
Molecular biology reports [Mol Biol Rep] 2019 Jun; Vol. 46 (3), pp. 2643-2655. Date of Electronic Publication: 2019 Mar 29.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Dordrecht, Boston, Reidel.
MeSH Terms:
Adipocytes/*drug effects
Estradiol/*pharmacology
Rilpivirine/*pharmacology
beta-Naphthoflavone/*pharmacology
3T3-L1 Cells/drug effects ; Adipogenesis/genetics ; Adipokines/metabolism ; Animals ; Cell Differentiation/drug effects ; Cytokines/metabolism ; Estradiol/metabolism ; Gene Expression/drug effects ; Humans ; Inflammation/drug therapy ; Leptin/genetics ; Lipid Metabolism/drug effects ; Mesenchymal Stem Cells/drug effects ; Mice ; Rilpivirine/metabolism ; beta-Naphthoflavone/metabolism
References:
Int J Obes Relat Metab Disord. 2001 Nov;25(11):1680-8. (PMID: 11753591)
Lancet. 2011 Jul 16;378(9787):229-37. (PMID: 21763935)
Physiol Res. 2007;56(4):375-81. (PMID: 16925464)
J Endocrinol Invest. 2014 Jun;37(6):533-9. (PMID: 24532267)
Antiviral Res. 2011 Aug;91(2):112-9. (PMID: 21619898)
J Clin Invest. 2006 Jul;116(7):1784-92. (PMID: 16823476)
Eur J Obstet Gynecol Reprod Biol. 1999 Mar;83(1):105-8. (PMID: 10221618)
J Dairy Sci. 2007 Aug;90(8):3742-50. (PMID: 17638985)
Drugs Today (Barc). 2005 Aug;41(8):547-55. (PMID: 16234878)
Arch Toxicol. 2000 Aug;74(6):329-34. (PMID: 11005679)
J Atheroscler Thromb. 2005;12(6):295-300. (PMID: 16394610)
HIV Med. 2012 Sep;13 Suppl 2:87-157. (PMID: 22830373)
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30. (PMID: 8650195)
AIDS Res Hum Retroviruses. 2012 May;28(5):437-46. (PMID: 21902621)
Am J Physiol Endocrinol Metab. 2003 Nov;285(5):E1072-80. (PMID: 12876073)
J Pharmacol Exp Ther. 2004 Oct;311(1):147-54. (PMID: 15150316)
Drug Metab Dispos. 2006 Jul;34(7):1081-9. (PMID: 16581946)
Diabetes. 2001 Jun;50(6):1425-31. (PMID: 11375344)
Diabetes. 2006 Oct;55(10):2849-55. (PMID: 17003352)
J Acquir Immune Defic Syndr. 2011 May 1;57(1):16-23. (PMID: 21317795)
Am J Clin Oncol. 1985 Apr;8(2):128-33. (PMID: 3914839)
Antimicrob Agents Chemother. 2012 Jun;56(6):3369-75. (PMID: 22430974)
Toxicol Sci. 2013 Sep;135(1):1-16. (PMID: 23771949)
J Clin Endocrinol Metab. 2001 Oct;86(10):5045-51. (PMID: 11600583)
Clin Infect Dis. 2014 Aug 1;59(3):425-34. (PMID: 24729492)
Clin Pharmacokinet. 2009;48(4):211-41. (PMID: 19492868)
Obesity (Silver Spring). 2010 Dec;18(12):2398-400. (PMID: 20706200)
J Biol Chem. 2007 Jun 29;282(26):19152-66. (PMID: 17468099)
Cytokine. 2015 Apr;72(2):130-4. (PMID: 25647267)
Endocrinology. 2000 Feb;141(2):649-56. (PMID: 10650946)
J Biol Chem. 1995 Nov 10;270(45):26746-9. (PMID: 7592907)
Environ Res. 2008 Sep;108(1):63-8. (PMID: 18649880)
Curr Opin HIV AIDS. 2007 Jul;2(4):282-92. (PMID: 19372900)
Lancet. 2011 Jul 16;378(9787):238-46. (PMID: 21763936)
Diabetologia. 1999 Jan;42(1):117-8. (PMID: 10027590)
AIDS. 2008 Jul 11;22(11):1293-8. (PMID: 18580608)
Curr Opin Endocrinol Diabetes Obes. 2008 Oct;15(5):403-8. (PMID: 18769210)
Antivir Ther. 2013;18(8):967-77. (PMID: 23714781)
Am J Physiol Endocrinol Metab. 2013 Jun 1;304(11):E1167-74. (PMID: 23531620)
Dis Markers. 2015;2015:450237. (PMID: 26693203)
Reprod Biol Endocrinol. 2012 Jun 15;10:45. (PMID: 22703959)
J Clin Endocrinol Metab. 2005 Sep;90(9):5324-8. (PMID: 15956078)
Chem Res Toxicol. 1998 Sep;11(9):1048-56. (PMID: 9760279)
Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21. (PMID: 18081738)
Obes Rev. 2001 Nov;2(4):239-54. (PMID: 12119995)
Endocrinology. 2006 Sep;147(9):4496-504. (PMID: 16740979)
J Endocrinol. 2002 Jan;172(1):155-62. (PMID: 11786383)
J Endocrinol. 2005 Sep;186(3):457-65. (PMID: 16135665)
Biochem Pharmacol. 2007 Feb 1;73(3):378-84. (PMID: 17113041)
Contributed Indexing:
Keywords: Adipocytes; Adiponectin; Estradiol; Leptin; Resistin and IL-8; Rilpivirine; β-Naphthoflavone
Substance Nomenclature:
0 (Adipokines)
0 (Cytokines)
0 (Leptin)
4TI98Z838E (Estradiol)
6051-87-2 (beta-Naphthoflavone)
FI96A8X663 (Rilpivirine)
Entry Date(s):
Date Created: 20190331 Date Completed: 20200106 Latest Revision: 20210109
Update Code:
20240105
DOI:
10.1007/s11033-019-04671-4
PMID:
30927158
Czasopismo naukowe
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor, recently developed as a drug of choice for initial anti-retroviral (ARV) treatment of HIV-1 infection, whereas estradiol is a major component of hormonal contraceptives. Both drugs have effects on lipid metabolism, impairment of adipocyte differentiation and alteration of adipose tissue distribution and function.This study investigated the effects of different concentrations of either rilpivirine or estradiol either alone or in combination on adipocyte differentiation and adipocytokines status in vitro in the absence and presence of β-naphthoflavone, (BNF),a potent agonist of the aryl hydrocarbon receptor. 3T3-L1 human pre-adipocytes were cultured and differentiated with different concentrations of treatment drugs. After 10 days of differentiation procedure, cells were examined for their morphology and viability. Glycerol,adiponectin, leptin, resistin and interleukin-8 (IL-8) were quantified using commercially available kits. The results show that either rilpivirine or estradiol individually or during their combination can evoke significant increases in glycerol release and a concomitant significant decrease of adiponectin from adipocytes. These effects were dose-dependent. The effects of combined treatments were much larger than individual concentration for each drug. Both drugs had little of no effect on leptin levels, except for a small decrease with 10 µM rilpivirine alone or when combined with estradiol. In addition, both drugs evoked small increases in the release of resistin and interleukin-8 with significant values at higher doses compared to untreated adipocytes.When adipocytes were pretreated with BNF, either rilpivirine or, estradiol or when combined evoked a much larger release in glycerol and a much larger decrease in adiponectin compared to the absence of BNF. In contrast, BNF pretreatment had little of no effect on either leptin, resistin or IL-8 metabolism compared to the results obtained in the presence of either rilpivirine or estradiol alone or in combination.These results show that rilpivirine and estradiol either alone or when combined or pretreated with BNF can evoke marked effects on glycerol and cytokines levels from adipocytes. However, their mechanism (s) in inducing adipogenesis warrants further investigation of different transcription factors at gene expression levels.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies